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LupeolPostprandial hyperglycaemia is characterized as the earliest symptom of diabetes and its management attenuates
several of the associated secondary complications. In this context, we investigated the role of ethanol extract of ba-
nana ﬂower (EF) for its antihyperglycaemic effects. The EF showed a strong inhibition towards α-glucosidase and
pancreatic amylasewhich play a vital role in clinicalmanagement of postprandial hyperglycaemia. Themajor active
compounds present in EF were identiﬁed as Umbelliferone (C1) and Lupeol (C2) using various spectroscopic
methods. C1 (IC50: 7.08 ± 0.17 μg/ml) and C2 (IC50: 7.18 ± 0.14 μg/ml) were found to inhibit α-glucosidase in a
non-competitive mode of inhibition, with low Ki values. Further, in vitro glycation assays showed that EF and its
compounds prevented each stage of protein glycation and formation of its intermediary compounds. EF, C1 and
C2 also exhibited a potent inhibition on aldose reductase with IC50 values of 2.25 ± 0.29, 1.32 ± 0.22 & 1.53 ±
0.29 μg/ml respectively. Our results suggest that, the observed potential of EF in antihyperglycaemic activity via
inhibition of α-glucosidase and in antidiabetogenic effect by inhibition of polyol pathway and protein glycation is
more likely to be attributed to the presence of C1 and C2.
© 2014 SAAB. Published by Elsevier B.V. All rights reserved.1. Introduction
Diabetes mellitus, a chronic metabolic condition is attributed to
an impaired regulation of carbohydrate and lipid metabolism by
inappropriate functioning of pancreatic hormone, insulin, which is
characterized by increased blood glucose levels. According to the
International Diabetes Federation (IDF), the number of diabetic pa-
tients is likely to reach 592 million by the year 2035 which will re-
ﬂect on the cost for treating it which is expected to reach US $548
billion, annually (International Diabetes Federation, 2013). Rapid
absorption of dietary carbohydrates aided by glycoside hydrolases
(α-glucosidase, α-amylase) converts them into simpler monosaccharide
units,which results in elevated blood glucose levels characterized as post-
prandial hyperglycaemia. This is distinguished as the earliest symptom of
diabetes, and the use of glycoside inhibitors is widely accepted as an efﬁ-
cient method in restraining postprandial hyperglycaemia by inhibiting
the release of free glucose units facilitating a smooth glucose proﬁle
(Ramith et al., 2014). Prolonged postprandial hyperglycaemia leads to
diverse secondary complications all of which result in a series of diabetic91 821 2548290.
a Prasad).
ghts reserved.complications viz., neuropathy, retinopathy and nephropathy. High blood
glucose levels cause a signiﬁcant ﬂux of glucose into the polyol pathway
to convert them into sorbitol by the action of aldose reductase (Kador
et al., 1985). Diabetic state leads to overproduction of sorbitol, which in
turn leads to its accumulation in tissues viz., nerves, kidney, retina and
lens due to impaired membrane permeability or reduced metabolism
by sorbitol dehydrogenase. Sorbitol accumulation is associated with var-
ious microvascular complications and cardiovascular diseases which can
be efﬁciently averted by inhibition of the key enzyme aldose reductase
(Peter et al., 1985). Other major concern in diabetes is glycation of pro-
teins resulting in partial loss of its activity as a consequence of perpetual
hyperglycaemia. A non-enzymatic nucleophilic addition reaction of the
carbonyl residue of sugar with the free amino group of proteins forming
a reversible Schiff base, which further forms amore stable Amadori prod-
uct constitutes the primary step in protein glycation. The Amadori prod-
ucts subsequently undergo a series of reactions via the dicarbonyl
intermediates resulting in less characterized compounds known as the
advanced glycation endproducts (AGEs)which subsequently accumulate
in the tissues and are responsible for the aetiology of diabetic micro- and
macro-vascular complications (Nessar, 2005). Consequently, the identiﬁ-
cation of compounds that inhibit each stage of glycation as well as the
formation of intermediary products in the pathway proves useful in
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complications (Samuel and James, 2003). Also, the glycated proteins
and AGEs by interfering in the signal transduction cascade induce the
generation of reactive oxygen species (ROS) concomitantly resulting in
oxidative stress, which constitutes key factors in the progression of sever-
al vascular complications in diabetes (Su-Yen andMark, 2008). The para-
mount method of protection from ROS mediated damage is provided by
the antioxidants which neutralize the generated free radicals. Collective-
ly, a therapy that involves an integrated antioxidant and antiglycation
properties with a potent α-glucosidase inhibition and lower α-amylase
inhibition can prove optimal in control of diabetes and its complications
(Prathapan et al., 2012).
In this regard, owing to the harmful effects of the long known syn-
thetic antidiabetic drugs, recently there has been increasing focus on
natural substances which have inhibitory potential on the development
of hyperglycaemia and its associated complications. Banana fruit con-
sumed worldwide is known for several beneﬁcial properties. Banana
ﬂower, one of the secondary products of banana cultivation, has been
consumed as vegetable in many countries (Joshi, 2000). It is a part of
traditional medicine, used in treatment of various disorders like kidney
stone and ulcers (Ivan, 2003). Its antihyperglycaemic effects have also
been accounted and included in some of the Ayurvedic formulations
in the treatment of diabetes (Bhaskar et al., 2011; Joshi, 2000). However,
the mechanism underlying and the active principles responsible for the
beneﬁcial role are less exploited. Hence, the aim of the present study
is to evaluate the potential of ethanol extract of banana ﬂower (EF)
in inhibiting α-glucosidase and α-amylase that are responsible for
hyperglycaemia as well as inhibition of aldose reductase and protein
glycation that are responsible for various diabetic complications.
Glycation markers at each stage of glycation viz., fructosamines (early
stage), protein carbonyls (intermediate stage) and AGEs (late stage)
were also evaluated. Besides, isolation of active compounds responsible
for the beneﬁcial properties was carried out. The ﬁndings could become
a rationale to include EF as an effective therapeutic adjunct for manage-
ment of hyperglycaemia and associated complications.
2. Materials and methods
2.1. Chemicals
Butylated hydroxyl anisole (BHA), 1,1-diphenyl-2-picrylhydrazyl
(DPPH), 2,2′-azinobis-3-ethylbenzthiazoline-6-sulfonate (ABTS),
phenazine methosulfate (PMS), nitro blue tetrazolium (NBT), gallic
acid, dinitro phenyl hydrazine (DNPH), L-cysteine, porcine pancreatic α-
amylase (EC 3.2.1.1), α-glucosidase (EC 3.2.1.20) from Saccharomyces
cerevisiae, p-nitrophenyl-α-D-glucopyranoside (pNPG), β-NADPH and
aminoguanidine were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Thiobarbituric acid (TBA), trichloro acetic acid (TCA), sodium car-
bonate and nicotinamide adenine dinucleotide-reduced (NADH)
were obtained from Sisco Research laboratories (Mumbai, India).
Acarbose (Glucobay, 50 mg) was obtained from Bayer India (Thane,
India). Reagents and solvents used for extraction and silica-gel for
column chromatography were procured from Merck (Mumbai, India).
All of the other reagents were of analytical grade.
2.2. Plant material
Immaculate inﬂorescences ofMusa sp. cv. Nanjangud rasa bale were
collected from banana cultivating farms of Nanjangud, Karnataka, India.
The specimen was identiﬁed by the Department of Horticulture,
Government of Karnataka, Mysore, India. Flowers were separated
from the inﬂorescence followed by discarding the spathe. The isolated
ﬂowers were cleaned, cut into small pieces and dried at 40 °C in an
oven. This was powdered using a homogenizer and further stored at
4 °C until use.2.3. Extraction
The coarse powder was subjected to hot extraction using ethanol in
a Soxhlet apparatus. Extraction was performed twice with 95% ethanol
(500ml) and ﬁltered. The resultingﬁltratewas concentrated under vac-
uumusing rotary evaporator (Rotavapor R-200, Buchi, Switzerland) and
the yield of ethanol extract was recorded. Subsequently, ethanol extract
of banana ﬂower (EF) was subjected to preliminary phytochemical
screening to identify the phytoconstituents present based on standard
protocols (Harbone, 1973). The total phenol content (TPC) for the EF
was estimated as per Shuxia et al. (2013).
2.4. α-Amylase inhibition assay
The α-amylase (EC 3.2.1.1, categorised as type-VI B porcine pancre-
atic α-amylase) inhibition was assayed according to the procedure
described by Worthington (1993) with slight modiﬁcations. The α-
amylase activity was determined, using soluble starch (1%) as a sub-
strate in 0.02 M sodium phosphate buffer (pH 6.9 with 0.006 M NaCl).
The enzyme (0.5 mg/ml) dissolved in 500 μl of 0.02 M sodium phos-
phate buffer (pH 6.9 with 0.006 M NaCl) and 500 μl (0–1000 μg/ml) of
EF (dissolved in DMSO) were pre-incubated for 10min at 25 °C. The re-
sidual α-amylase activity was evaluated by adding 1% starch solution
(500 μl) and incubation at 25 °C for 15 min. The reaction was stopped
by adding 1000 μl of DNS reagent and kept in a boiling water bath
(85 °C) for 5 min. The resulting mixture was diluted by 10 ml distilled
water and absorbance (A) was measured at 540 nm in a spectropho-
tometer (Shimadzu UV-1800). Subsequently, the absorbance of blank
(without enzyme) was subtracted from each test sample (EF) and the
results were compared with the control (without analyte). Acarbose
was used as a positive control. The α-amylase inhibitory activity was
expressed in percent inhibition.
Inhibition %ð Þ ¼ Acontrol−Asample
 
=Acontrol  100
IC50 valueswere determined from a curve relating the % inhibition of
each sample to the concentration of sample.
2.5. Yeast α-glucosidase inhibition assay
The yeast α-glucosidase (EC 3.2.1.20, categorised as type-1 α-
glucosidase) inhibitionwas assayed using the substrate pNPG according
to the modiﬁed method described by Worawalai et al. (2012). In short,
700 μl phosphate buffer (50 mM, pH 6.8) and 100 μl EF with varying
concentrations dissolved in dimethyl sulfoxide (DMSO) were mixed
prior to the addition of 100 μl of yeast α-glucosidase (0.4 U/ml). One
unit of α-glucosidase is deﬁned as the amount of enzyme liberating
1 μmol of p-nitrophenol formed from pNPG per minute under the
assay conditions speciﬁed. The mixture was pre-incubated for 10 min
at 37 °C. After incubation, 100 μl of 0.5 mM pNPG solution in 50 mM
phosphate buffer (pH 6.8) was added and the reaction was maintained
at 37 °C for 20min. The reactionwas terminated by adding 250 μl 0.1M
Na2CO3. Enzyme activity was determined bymeasuring the absorbance
of the liberated p-nitrophenol from pNPG at 405 nm using micro-plate
reader (Spectramax 340, Molecular Devices, Sunnyvale, USA). The
absorbance was compared with the control, containing buffer instead
of test sample. Acarbose was used as a positive control. The results
were expressed as percent α-glucosidase inhibition obtained using
the formula given below:
Inhibition %ð Þ ¼ Acontrol−Asample
 
=Acontrol  100:
Each experiment was performed in triplicates, along with appropri-
ate blanks. The concentration required to inhibit 50% of the α-
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as the IC50.
2.6. Aldose reductase (AR) inhibition assay
Human recombinant AR activitywasmeasured according to the pro-
cedure of Nishimura et al. (1991) with slight modiﬁcations. In brief, re-
action mixture consisted of 870 μl sodium phosphate buffer (100 mM,
pH 6.2), 50 μl NADPH (3 mM), 10 μl AR enzyme (0.2 U/ml) and 20 μl
of EF (dissolved in DMSO) with diverse concentration, in a ﬁnal volume
of 1000 μl. The enzyme reaction was initiated by the addition of 50 μl
substrate (DL-glyceraldehyde, 5 mM) and incubated for 3 min at 25 °C.
Enzyme activity was determined by measuring the absorbance (de-
crease in NADPH absorption) at 340nmover a 10min period. The inhib-
itory activitywas evaluated by comparing the absorbance change of test
to that of the control. All the tests were performed in triplicates and the
IC50 was calculated as described in α-amylase inhibition assay.
2.7. Evaluation of antiglycation potential
2.7.1. In vitro bovine serum albumin (BSA) glycation
The formation of albumin glycation was assayed using BSA/fructose
system according to themodiﬁedmethod described byMcPherson et al.
(1988). The assay was performed by adding 1 ml BSA (10 mg/ml) in
4 ml assay system containing 1 ml fructose (300 mM), 1 ml phosphate
buffer (100 mM, pH 7.4 with 0.02% sodium azide) along with EF (test)
or aminoguanidine (positive control) at different concentrations. Reac-
tion mixture was incubated for 21 days at 37 °C in sterile conditions.
Prior to incubation,ﬁltration of reactionmixture through 0.22 μmmem-
brane ﬁlters was performed under aseptic conditions to sustain sterility.
Subsequently, samples free of microbial contamination were subjected
to dialysis against phosphate buffer (100 mM, pH 7.4) and kept frozen
at−80 °C until analysis. The control (EF replaced by carrier solvent)
was sustained under analogous state and all the incubations were per-
formed in triplicates.
2.7.2. Analysis of AGE formation
Theﬂuorescence intensities of the resultingAGE formed (ﬂuorescent
products) from albumin glycation and control were determined using
spectral scanning multimode reader (Thermo Scientiﬁc, Varioskan
Flash) at excitation and emission wavelengths of 370 and 440 nm
(with slit = 10 nm) respectively. The ﬂuorescence of control and test
(EF) was blanked against BSA and apposite treatment controls. The
corrected ﬂuorescence readings (F) of the control (Fc) and the test (FT)
were acquired to resolve the percent inhibition of AGE formation and
calculated as follows:
Inhibition %ð Þ ¼ Fc–FTð Þ=Fc  100:
2.7.3. Analysis of fructosamine
The formation of fructosamine (an Amadori product) in the glycated
BSA and the control was assessed using NBT assay described by Johnson
et al. (1983) with slight modiﬁcations. In brief, 200 μl glycated samples
and control were mixed with 0.8 ml of carbonate buffer (100 mM,
pH 10.4) and 0.5mMNBT and incubated at 37 °C. Absorbancewasmea-
sured at 530nm in a spectrophotometer at 10 and 15min time intervals.
The concentration of fructosamine was determined using 1-deoxy-1-
morpholino-fructose (1-DMF) as standard. The inhibitory activity
against fructosamine was calculated by comparing the absorbance
change of test samples (AT) to that of the control (Ac), where the test
sampleswere replaced by carrier solvent and calculated by the equation
below:
Inhibition %ð Þ ¼ Ac–ATð Þ=Ac  100:2.7.4. Analysis of protein carbonyl content
The carbonyl group, a marker for protein oxidative damage was
assayed using glycated BSA according to the method described by Koji
et al. (1998)with slightmodiﬁcations. In brief, 400 μl of glycated protein
samples and control weremixed with 600 μl of DNPH (0.1% in 2MHCl)
and incubated for 60 min at 37 °C. The proteins in the reaction mixture
were precipitated with 500 μl TCA (20%w/v). Consequently, the precip-
itate was cleansed thrice with ethanol:ethyl acetate (1:1 v/v) following
centrifugation. All the preparationswere performed at 4 °C. The protein
sample was then solubilised with 2 ml of 8 M guanidine chloride and
absorbance was recorded at 365 nm. The results were expressed as
nmol carbonyl/mg protein based on molar extinction coefﬁcient
( 365 nm = 21 mM per cm) of DNPH. Percent inhibition of protein
carbonyl content by test samples was calculated using the equation as
described for fructosamine.
2.7.5. Analysis of protein thiol content
The free thiols in the glycated samples and the control were estimat-
ed by Ellman's method (Ellman, 1959). The concentration of free thiols
was determined using L-cysteine as standard and expressed as nmol/mg
protein. Results were expressed as percent protection to protein thiols
by test samples in comparison with the control.
2.8. Antioxidant assays
In this study, three principlemethods, DPPH free radical, ABTS cation
radical and superoxide anion radical scavenging activities were
employed and measured as per Nurhanani et al. (2008). Radical scav-
enging potential was expressed as EC50 values. An EC50 value represents
50% of free, cation and anion radicals scavenged by the test samples. All
the samples were analysed in triplicates. BHA was used as positive
control.
2.9. Assay of lipid peroxidation inhibition
The antioxidative action of EF and its constituentswas determined in
a liposome model (Lipid peroxidation inhibition in biological systems)
as described by Meghashri et al. (2010). Results were expressed as
EC50 values as described in antioxidant assays.
2.10. Reducing power assay
Reducing power of iron ion was determined according to the meth-
od reported by Yen et al. (2002) with slight modiﬁcations. In brief,
0.75 ml EF of varying concentrations was mixed with equal volume of
0.2M phosphate buffer (pH 6.6) and 0.75ml 1% potassium ferricyanide.
Themixturewas incubated at 50 °C for 20min and subsequentlymixed
with 0.75 ml TCA (10%) and centrifuged at 3000 rpm for 10 min. The
supernatant was mixed with equal volume of distilled water and 0.1%
ferric chloride (0.5 ml). The absorbance of the resulting solution was
measured at 700 nm. Ascorbic acid was used as reference standard
and phosphate buffer as blank solution. An increase in the absorbance
of the reaction mixture was taken as a measure of reducing power.
2.11. Metal ion chelating activity
The ferrous ion chelating activity was measured by the ferrous ion–
ferrozine complex at 562 nm. The ability of the test samples to chelate
ferrous ion was carried out as described by Meghashri et al. (2010).
2.12. Isolation and identiﬁcation of bioactive components in EF
The crude EF (25 g each)was subjected to silica-gel (100–200 mesh)
column (length 100 cm and 3 cm diameter) chromatography (elution
rate of 2 ml/min ﬂow with a total elution of 600 ml). It was eluted
with diverse solvents (100 ml each) ranging from non-polar to polar
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methanol and water. The fractions were collected and spotted over
pre-coated silica gel F254 plates (20 × 20 cm, Merck, Germany). The
optimum resolution was attained in the combination of solvent system
n-butanol, water and acetic acid (5:4:1 v/v). To visualize the spot, TLC
platewas exposed to iodine fumes. The fractions (Fr)with similar reten-
tion factor (Rf) in TLC pattern were pooled together. Hence, methanol
(Fr. I-16–20) and ethanol (Fr. I-21–25) fractions with same Rf were
pooled, yet again subjected to silica-gel column chromatography and
eluted stepwise with linear gradients of methanol:ethanol (90:10;
80:20; 70:30; 60:40; 50:50; 20:80; 100:0 v/v). A single spot on TLC
with n-butanol, water and acetic acid (5:4:1 v/v) mobile phase led to
the isolation of Umbelliferone (96 mg) and Lupeol (90 mg) from Fr. II
(36–40) and Fr. II (46–50) fractions respectively. The amount of com-
pounds (1) and (2) were found to be 0.38% and 0.36%, respectively.
2.12.1. Nuclear magnetic spectroscopy (NMR) analysis
The NMR spectra were recorded on a Bruker DRX-400 spectrometer
(Bruker Biospin Co., Karlsruhe, Germany) with 1H NMR at 400MHz and
13C NMR at 100 MHz. The isolated compounds were prepared using
deuterated solvent with tetramethylsilane (TMS) as an internal stan-
dard in 5 mm NMR tubes. Data were measured in CDCl3 with chemical
shifts according to the TMS signal and were expressed in parts per
million (δ).
2.12.2. High-performance liquid chromatography mass spectrometer
The mass spectrum was obtained using LCMS2010A (Shimadzu,
Japan) having probes APCI & ESI. The separation was performed on a
C-18 column (Agilent Technologies, Palo Alto, CA, USA) using a mobile
phase consisting of methanol/water (90:10). Flow rate was maintained
at 0.2ml/min and the elutes weremonitored at 254 nm. Themass spec-
trum (MS) was obtained in ESI mode at CDL temperature at 250 °C,
block temperature at 200 °C, detector voltage at 1.6 kV and with nitro-
gen nebulizer gas ﬂow at 1.5 l/min.
2.12.3. Other analyses
The IR spectrawere recorded using KBr discs on a NICOLET 380 FT IR
spectrometer (Thermo Fisher Scientiﬁc, France) in the range of 400 to
4000 nm. The ultraviolet (UV) spectra of the compounds in methanol
were recorded on a Shimadzu UV-1800 spectrophotometer. The melt-
ing points were determined on an electrically heated VMP-III melting
point apparatus and were uncorrected. Further elemental analysis of
the compounds was performed on a Perkin Elmer 2400 elemental
analyzer.
2.13. Kinetics of α-glucosidase inhibition
The enzyme kinetics on inhibition of α-glucosidase activity by the
isolated compounds were studied using diverse concentrations of sub-
strate against IC20, IC40 and IC60 inhibitory concentrations of the isolated
compounds. The type of inhibition, Km and Vmax were determined by
double reciprocal plot (Lineweaver and Burk, 1934) of the substrate
concentration and the velocity (1/V versus 1/[pNPG]). Further, the in-
hibitory constant (Ki) was determined by Dixon plot (Dixon, 1953).
2.14. Statistical analysis
The experiments were done in triplicates. Results were expressed
as mean ± SE. Statistical comparisons between the treatment groups
and control were performed by one-way analysis of variance (ANOVA),
followed by Duncan's multiple range test using SPSS Software (version
21.0, Chicago, USA). The results were considered statistically signiﬁcant
if the ‘p’ values were 0.05 or less. GraphPad PRISM software (version
4.03) was used for calculating IC50 values.3. Results
In this study, EF exhibited an effective inhibition onα-glucosidase at
a more signiﬁcant level than the drug acarbose, with a higher free radi-
cal scavenging activity in all the assays tested. In addition, EF was effec-
tive in inhibiting the polyol pathway by inhibition of the key enzyme,
aldose reductase and prevented the formation of advanced glycation
end products remarkably better than the positive control. These ﬁnd-
ings suggested the presence of potential inhibitory compounds in the
extract. Hence an attempt was made to identify the potential bioactive
principles in EF responsible for its antiglycaemic activity.
3.1. Isolation and identiﬁcation of Umbelliferone and Lupeol from EF
The preliminary phytochemical investigation of EF showed the
presence of triterpenoids, coumarins and phenolic compounds. To
characterize the bioactive components responsible for inhibition of
α-glucosidase, EFwas subjected to column chromatography. Repeat-
ed chromatographic separations through silica gel column chroma-
tography lead to the identiﬁcation of Umbelliferone and Lupeol
(Fig. 1). The structural elucidation of the compounds was deter-
mined on various physicochemical and spectroscopic methods (UV,
IR, 1H NMR, 13C NMR and MS). The elucidation of their structures is
as follows.
Umbelliferone (C1): obtained from Fr. II (36–40) as light yellow
semi-solid. m.p. 225 °C. UV (MeOH): λ max 324 nm. IR (KBr) 3610–
3590 cm−1 (O–H). 1H NMR (CDCl3, 400 MHz): δ 4.6 (1H, bs, OH), 6.46
(1H, d, H-3), 6.61 (1H, s, H-8), 6.66 (1H, d, H-6), 7.44 (1H, d, H-5), 7.8
(1H, d, H-4). 13C NMR (CDCl3, 100 MHz): δ 162.6 (C-2), 116.2 (C-3),
145.3 (C-4), 128.4 (C-5), 112.6 (C-6), 157.5 (C-7), 108.6 (C-8), 152.2
(C-9), 120.2 (C-10). EIMS for C9H6O3m/z: 162 [M+1]. Analytical calcu-
lated data for (C9H6O3): C, 66.67; H, 3.73%. Found C, 66.69; H, 3.75%. The
identity of the compound was deciphered on the basis of the above re-
sults as well in comparisonwith the NMR andMS data in the literatures
(Rajbir et al., 2010).
Lupeol (C2): obtained from Fr. II (46–50) as creamish yellow
semi-solid. m.p. 214 °C. UV (MeOH): λ max 200 nm. IR (KBr)
3610–3590 cm−1 (O–H). 1H NMR (CDCl3, 400 MHz): δ 4.58, 4.62
(2H, s, H-29a, 29b), 3.19 (1H, dd, J = 4.79, 11.00 Hz, H-3), 0.74,
0.77, 0.86, 0.95, 0.96, 1.05, 1.26 (each 3H, s, Me × 7). 13C NMR
(CDCl3, 100 MHz): δ 151.3 (C-20), 109.4 (C-29), 79.5 (C-3), 55.4
(C-5), 50.7 (C-9), 48.4 (C-18), 48.5 (C-19), 43.4 (C-17), 43.3 (C-14), 41.2
(C-8), 40.3 (C-22), 39.2 (C-13), 38.6 (C-4), 38.7 (C-1), 37.5 (C-10), 35.6
(C-16), 34.4 (C-7), 30.2 (C-21), 28.3 (C-23), 27.6 (C-15), 27.7 (C-12),
25.1 (C-2), 21.3 (C-11), 19.4 (C-30), 18.2 (C-6), 18.3 (C-28), 16.4 (C-25),
16.5 (C-26), 15.6 (C-24), 14.6 (C-27). EIMS for C30H50O m/z: 427
[M + 1]. Analytical calculated data for (C31H52O): C, 84.44; H,
11.81%. Found C, 84.47; H, 11.85%. On the basis of the above results
as well in comparison with the NMR and MS data in the literature
(Aynilian et al., 1972), compound (2) was identiﬁed as Lupeol.
3.2. Inhibitory effects on yeast α-glucosidase and α-amylase
In vitro α-glucosidase inhibitory studies recognized that EF and its
active compounds had effective inhibitory potential. The IC50 values
were found to be 7.79, 7.08 and 7.18 μg/ml for EF, C1 and C2 respective-
ly. Acarbose, investigated under same conditions had IC50 value of
9.68 μg/ml, therefore, EF, C1 and C2 showed higher inhibitory effect in
this assay. In terms of IC50 values, it is evident that C1 and C2 possessed
a strong inhibition on yeastα-glucosidase andwere signiﬁcantly higher
(p b 0.05) than acarbose and EF (Table 1). The inhibition ascended in
the order: C1 N C2 N EF N Acarbose.
Furthermore, similar studieswere conducted to evaluatewhether EF
and its constituents also inhibitedα-amylase, another key carbohydrate
hydrolyzing enzyme. The 50% inhibition of α-amylase by EF and its
active compounds is detailed in Table 1. Results showed that C1 (IC50:
Coarse powder
Sequential Soxhlet extraction
Ethanol extract 
Silica gel chromatography -I 
Methanol (Me)
Fr.I (16-20)
Water
Fr.I (26-30)
Ethanol (Et) 
Fr.I (21-25)
Acetone
Fr.I (11-15)
Petroleum ether:chloroform 
(1:1)-Fr.I (1-5)
Ethyl acetate 
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Fr.II (31-35)
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50:50
Fr.II (51-55)
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Fig. 1. Separation scheme of active compounds from ethanol extract of banana ﬂower and structures of isolated compounds.
58 R. Ramu et al. / South African Journal of Botany 95 (2014) 54–6332.26 μg/ml) possessed the highest inhibitory activity as compared to
C2 (IC50: 32.90 μg/ml), whereas EF (IC50: 36.05 μg/ml) had the lowest
inhibitory effect. Theα-amylase inhibitory effect (based on IC50 values)
of EF, C1 and C2was comparatively lower (p b 0.05) than the therapeu-
tic drug acarbose (IC50: 29.71 μg/ml).
3.3. Kinetic analysis of α-glucosidase inhibition by C1 and C2
C1 and C2 were selected for further kinetic inhibition experiments
against yeast α-glucosidase since it wielded a remarkable inhibitory
activity. For kinetic studies, enzyme was incubated with designated
concentrations of substrate pNPG in the absence (control) or presence
of IC20, IC40 and IC60 inhibitory concentrations of C1 and C2. Mode of in-
hibition, [Km] and [Vmax] values were determined by graphical meansTable 1
Inhibitory activities of ethanol extract of ﬂower (EF) and its isolated compounds on α-amylase
Enzymes IC50x,y (μg/ml)
EF Umbellifero
α-Amylase 36.05 ± 0.48c 32.26 ± 1.8
α-Glucosidase 7.79 ± 0.11b 7.08 ± 0.1
Aldose reductase 2.25 ± 0.29b 1.32 ± 0.2
x Values are expressed as mean ± SE. Means in the same row with distinct superscripts are
y The IC50 value is deﬁned as the inhibitor concentration to inhibit 50% of enzyme activity u
⁎ Quercetin was used as positive control in aldose reductase assay.using Lineweaver–Burk plots. Lineweaver–Burk plots revealed that the
intersecting point for different concentrations of C1 (Fig. 2A) and C2
(Fig. 2B) arises from the same x-intercept as uninhibited enzyme
other than diverse slopes and y-intercepts. With the increasing concen-
trations of C1 and C2, both the slope and the vertical axis intercept
increased, whereas, the horizontal axis intercept (−1/ Km) remained
the same. The kinetic results established that C1 and C2 retarded
the maximum velocity (Vmax) of the reaction (with increasing concen-
trations) catalysed byα-glucosidase withoutmuch change in Km values
(Table 2). These results indicated that the mechanism of α-glucosidase
inhibition was reversible, corresponding to the classical pattern of non-
competitive inhibition. The inhibitory constant (Ki), determined from
Dixon plots for α-glucosidase was 1.61 and 2.87 μg of C1 and C2
respectively., α-glucosidase and aldose reductase enzymes.
ne Lupeol Acarbose/⁎quercetin
0b 32.90 ± 1.18b 29.71 ± 1.51a
7a 7.18 ± 0.14a 9.68 ± 0.48c
2a 1.53 ± 0.29a ⁎3.42 ± 0.14c
signiﬁcantly different (p ≤ 0.05) as separated by Duncan's multiple range test.
nder assay conditions.
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Fig. 2. Lineweaver–Burk plot of substrate dependent enzyme kinetics on inhibition of
α-glucosidase activity by Umbelliferone (A) and Lupeol (B). α-Glucosidase was incu-
bated with diverse concentrations of p-nitrophenyl-α-D-glucopyranoside (pNPG,
0.25–4 mM) in the absence or presence of Umbelliferone and Lupeol at IC20, IC40
and IC60 inhibiting concentrations.
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The inhibitory effect of EF and its constituents on aldose reduc-
tase was found to be 2-fold higher than quercetin, the phenolic in-
hibitor. EF inhibited aldose reductase with an IC50 of 2.25 μg/ml
(Table 1). C2 (IC50: 1.53 μg/ml) isolated from EF was found to be a
potent inhibitor, but nonetheless the inhibition was slightly lower
than C1 (IC50: 1.32 μg/ml). On the whole, EF and its constituents
were stronger inhibitors (p b 0.05) than quercetin.
3.5. Antioxidant ability and TPC
The free radical scavenging ability of EF and its constituents was
measured by employing a battery of in vitro assays viz., DPPH, ABTS
and Superoxide while BHA was used as a positive control. Results
expressed as EC50 values (μg of tests per ml) summarized in Table 3, in-
dicated that the isolated compounds C1 and C2 were comparatively
higher (pb 0.05) than EF in radical scavenging activities. In all the assays
used in this study, EF, C1 and C2 were 2-fold effective than BHA, and
activities ascended in the order C1 N C2 N EF N BHA. In general, C1 isolat-
ed from EF exhibited a higher free radical scavenging activity in threeTable 2
Enzyme kinetics of α-glucosidase by Umbelliferone (1) and Lupeol (2).
Compounds Treatment Mode of inhibitionx
1 Control Non-competitive
IC20 3 μg
IC40 6 μg
IC60 9 μg
2 Control Non-competitive
IC20 3 μg
IC40 6 μg
IC609 μg
x Inhibition mode was determined from Lineweaver and Burk plot.
y Ki = dissociation constant.
z Values are expressed as mean ± SE.antioxidant assayswhile C2was relatively lower (based on EC50 values)
but statistically similar (p b 0.05) to C1. The results revealed that C1 and
C2 possess strong antioxidant ability and are signiﬁcantly higher
(p b 0.05) than the positive control.
The ethanol extract of banana was found to have high phenolic
content (227 mg GAE/g) with an extraction yield of 125.08 g/kg. The
results implied that the content of total phenols was concentrated in
the EF and the compounds isolated from these active extract showed
high TPC in the same order: C1 (36.52) N C2 (28.28 mg GAE/g respec-
tively) of antioxidant assays.
3.6. Reducing power
The increase in the absorbance at 700 nm of the reaction mixture
caused by the EF, C1 and C2 was descriptive of their increased reducing
power. As shown in Fig. 3E it is evident that EF and its constituents
exhibited increased reducing power with the increased concentration
as ascorbic acid. The reducing power decreased in the order of ascorbic
acid N C1 N C2 N EF, in the increasing concentrations (0.2–1 mg/ml).
3.7. Lipid peroxidation inhibitory activity
The lipid peroxidation inhibitory activity of EF and its constituents is
shown in Table 3. The ethanolic extract (EC50: 36.43 μg/ml) displayed
1.3 fold higher inhibitory activity compared to the standard antioxidant,
BHA (EC50: 46.72 μg/ml). The EC50 value for C2 was found to be
27.97 μg/ml and C1 showed an EC50 value of 23.81 μg/ml, which is
more active than C2. All the compounds and EF exhibited a higher in-
hibitory effect, with the order: C1 N C2 N EF N BHA.
3.8. Metal chelating activity
Activity of test samples on chelating the ferrous ions is shown
in Table 3. EF showed 50% chelating ability at the concentration of
52.53 μg/ml. The EC50 value of BHA was 67.58 μg/ml. Both the com-
pounds C1 (33.89 μg/ml) and C2 (39.20 μg/ml) exhibited higher metal
chelating activity than BHA. The results illustrated that EF and its
constituents possess ion chelating effects and are signiﬁcantly higher
(p b 0.05) than BHA.
3.9. Antiglycation potential at various levels
The inhibitory effects of diverse concentrations of EF, C1, C2 and
aminoguanidine (25, 50 and 100 μg/ml) on early glycation product
(fructosamine), intermediate (protein carbonyls) and late stage
glycation moieties (AGEs) after 3 weeks of incubation are shown in
Fig. 3A–C. Incubation with EF and its constituents inhibited albumin
glycation at various stages in a dose dependent fashion. At the end of
the study period, it was evident that both C1 and C2 exhibited higher
inhibitory activities (in all the levels) compared to EF with diverse
concentrations. At a concentration of 100 μg/ml, the formation ofKm (mM) Vmax (103(μM/min)−1) Ki (μg)y,z
0.85 76.92 1.61 ± 0.13
0.94 28.57
0.96 17.54
0.95 12.35
0.80 25.64 2.87 ± 0.16
0.81 12.66
0.82 9.01
0.83 6.37
Table 3
Yield, antioxidant activity and total phenolic contents (TPC) of ethanol extract of ﬂower (EF) and its isolated compounds.
Sample Yield (g/kg) TPC (mg GAE/g) EC50x,y (μg/ml)
Radical scavenging activities Lipid peroxidation Metal chelation
DPPH ABTS Superoxide
EF 125.08 ± 1.84b 227.08 ± 1.92c 28.85 ± 3.42b 27.17 ± 1.81b 53.39 ± 4.06b 36.43 ± 0.83c 52.53 ± 0.22c
Umbelliferone 3.85 ± 0.14b 36.52 ± 2.28b 21.70 ± 0.37a 21.99 ± 0.28a 47.39 ± 1.68a 23.81 ± 1.60a 33.89 ± 1.34a
Lupeol 3.63 ± 0.09a 28.28 ± 1.27a 24.14 ± 1.82a 22.05 ± 0.80a 48.79 ± 0.61a 27.97 ± 1.16b 39.20 ± 1.64b
BHA – – 40.43 ± 0.81c 32.31 ± 1.22c 73.04 ± 0.93c 46.72 ± 0.42d 67.58 ± 1.05d
x Values are expressed as mean ± SE. Means in the same column with distinct superscripts are signiﬁcantly different (p ≤ 0.05) as separated by Duncan's multiple range test.
y The EC50 value is deﬁned as the effective concentration of the test samples to show 50% of antioxidant activity under assay conditions.
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the range of 85 to 90% (Fig. 3A), while the protein carbonyl compounds
was found to be inhibited at 80–86% (Fig. 3B) and in the presence of C1
it wasmaximally diminished. Fluorescence studies on AGEs as illustrat-
ed in Fig. 3C implied that EF, C1 and C2 can inhibit them in the range of
71–82%. It is worth mentioning that EF, C1 and C2 exhibited higher in-
hibition compared to a known inhibitor aminoguanidine at diverse con-
centrations on 21 day incubation.
Subsequently, Table 4 gives the amount of fructosamine and protein
carbonyl content in the various incubated test samples (EF, C1 and C2)
with aminoguanidine at 1, 2 and 3 weeks. The results showed that the0
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C1 exhibited the maximum inhibition in the formation of fructosamine
followed by C2 and EF. Aminoguanidine also showed inhibition but was
signiﬁcantly lower (p b 0.05) than EF and its constituents. Similarly the
addition of fructose to BSA increased the amount of protein carbonyl
formation compared to BSA alone. It was found that suppression of
protein carbonyl formation by EF and its constituents was signiﬁcantly
higher (p b 0.05) than aminoguanidine, when compared to BSA incu-
bated with fructose.0
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Table 4
Effects of ethanol extract of ﬂower (EF) and its isolated compounds on fructosamine, protein carbonyl and thiol group content in BSA/fructose system after incubation for 3 weeks.
Week BSA BSA/fructose EF Umbelliferone Lupeol Aminoguanidine
A. Fructosamine (mmol/mg protein)
1 – 37.30 ± 0.51e 26.20 ± 0.34c 22.22 ± 0.38a 25.04 ± 0.06b 30.12 ± 0.20d
2 – 45.43 ± 0.49e 27.40 ± 0.45c 22.52 ± 0.47a 25.70 ± 0.51b 32.12 ± 0.20d
3 – 51.30 ± 0.10e 29.49 ± 0.43c 23.62 ± 0.11a 27.07 ± 0.06b 33.18 ± 0.18d
B. Protein carbonyl content (nmol/mg protein)
1 0.47 ± 0.01a 0.92 ± 0.07f 0.61 ± 0.27d 0.56 ± 0.63b 0.58 ± 0.19c 0.72 ± 0.09e
2 0.48 ± 0.05a 2.54 ± 0.23f 0.66 ± 0.30d 0.58 ± 0.44b 0.61 ± 0.11c 0.69 ± 0.56e
3 0.48 ± 0.39a 4.42 ± 0.31f 0.69 ± 0.11d 0.61 ± 0.05b 0.65 ± 0.10c 0.75 ± 0.02e
C. Thiols group (nmol/mg protein)
1 1.89 ± 0.03d 1.12 ± 0.08c 0.85 ± 0.02b 0.74 ± 0.02a 0.77 ± 0.01a 0.86 ± 0.03b
2 1.88 ± 0.02d 1.10 ± 0.07c 0.88 ± 0.03b 0.77 ± 0.01a 0.80 ± 0.04a 0.92 ± 0.04b
3 1.88 ± 0.12d 1.14 ± 0.03c 0.93 ± 0.02b 0.79 ± 0.01a 0.82 ± 0.05a 0.95 ± 0.05b
Values are expressed as mean ± SE. Means in the same row with distinct superscripts are signiﬁcantly different (p ≤ 0.05) as separated by Duncan's multiple range test.
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modiﬁcation was investigated in the present experimental conditions.
Treatment with EF and its constituents provided strong shielding from
denaturation i.e. signiﬁcant improvement in the thiol levels. Table 4
depicts the content of obtainable free thiol groups and oxidative modi-
ﬁcation of BSA on EF and its constituents. As depicted in Fig. 3D, both the
compounds and EF illustrated a remarkable protection against thiol
oxidation in a dose dependent fashion. At a concentration of 100 μg/ml,
results showed that thiols shielding values ranged from 80–91% in the
presence of EF, C1 and C2. For comparison, aminoguanidine at
100 μg/ml showed 78% thiol group protection under similar assay
conditions.
4. Discussion
Diabetes mellitus is a chronic metabolic complication withmultifac-
torial effects. Characterized by a hyperglycaemic state, diabetes is
closely associated to several other complications of the kidney, eye
and heart collectively induced by the excessive oxidative stress,
augmented formation of AGE and enhanced activation of aldose reduc-
tase-associated polyol pathway (Michael, 2001). Successful manage-
ment of hyperglycaemia is a prerequisite to organize the frequency,
advancement, and seriousness of diabetic complications. Conversely,
use of a single therapeutic procedure has unfortunately not been
successful in negating all the complications caused by the high level of
glucose in blood. Hence, auxiliary adjunct rehabilitations, such as α-
glucosidase inhibitors, AR inhibitors, antiglycation agents and antioxi-
dants could be viable remedial choice to constrict the toxic impacts of
glucose. Numerous studies have demonstrated the adequacy of the un-
reﬁned plant concentrate and also its bioactive mixes in bringing down
blood glucose levels (Geetanjali et al., 2010). Bananaﬂower, being an in-
cidental or secondary product of the banana cultivation, is known to
have hypoglycaemic impacts and was used to treat diabetes in conven-
tional medicine (Joshi, 2000). Recent work in this regard, provided a
stronger evidence of its antioxidant potential and hypoglycaemic effects
(Dhanabal et al., 2005; Pari and Maheswari, 1999) on alloxan induced
diabetic rats. However, a detailed study on the mechanism underlying
this role as well as the active principles corresponding to this biological
effect is deﬁcient and so in this study, we have focused on the antidia-
betic prospective of EF against multiple targets involved in the patho-
genesis of diabetes and its complications.
Mammalian α-glucosidases present on the brush border of the
epithelial cells of the small intestine and α-amylase secreted by the
pancreatic cells are the key enzymes in thehydrolysis of starch to free glu-
cose units, consequence of which is the postprandial hyperglycaemia.
Use of the enzyme inhibitors over the past few decades, has assisted in
delaying the disease progression by reduction of hyperglycaemic effect
(Casirola and Ferraris, 2006). In the present investigation, the banana
ﬂower extracted with ethanol exhibited a notable inhibition against α-glucosidase enzyme in comparison with the therapeutic drug acarbose.
Further, the repeated silica gel column chromatography of EF led to the
isolation of yellow semi-solid and creamish yellow semi-solid com-
pounds which were identiﬁed analytically pure by thin layer chromatog-
raphy. Various bioanalytical techniques (UV, IR, 1H NMR, 13C NMR and
MS) determined that these two compounds were Umbelliferone and
Lupeol, belonging to the coumarin and triterpenoids family respectively.
For bioevaluation studies, Umbelliferone and Lupeol isolated frombanana
ﬂower were tested for their ability to operate an antihyperglycaemic ac-
tivity by targeting the key enzymes of the carbohydrate metabolism.
Umbelliferone is known to be a potent antirheumatic, antipyretic and an-
algesic compound (Molnar and Garai, 2005), while, Lupeol is known for
its antiinﬂammatory and anticancerous effects (Mohammad, 2009).
Also, both the compounds have been reported to encompass signiﬁcant
biological activities suggesting its effectiveness in treatment of various
metabolic disorders (Margareth and Miranda, 2009; Wal et al., 2011;
Aoife and Richard, 2004; Revathi and Manju, 2013). However, its role
with regard to antihyperglycaemia has not been reported to date. In our
study, Umbelliferone and Lupeol isolated from EF were proved to be
two α-glucosidase inhibitors, of which Umbelliferone was the most po-
tent one. Further, in order to identify the mechanism underlying this in-
hibition, a Lineweaver–Burk plot was prepared from the kinetics data
which indicated a reversible, non-competitive type of inhibition, with
low Ki values. The results illustrated that these active principles bind to
a site other than the active site of the enzyme thereby retarding the en-
zyme substrate reaction,without competingwith the substrate for the ac-
tive site of the enzyme. A similar ﬁnding on non-competitive inhibition
was shown byGenistein, a soy isoﬂavone (Lee and Lee, 2001). In contrast,
EF and its constituents were assessed for its inhibition on another key
carbohydrate hydrolyzing enzyme α-amylase. The inhibitory effect on
α-amylasewas relatively low than that of acarbose. In general, the results
showed that extract and its active compounds had a strong inhibitory
activity onα-glucosidase andmild inhibition overα-amylase. Yet, our re-
sults are in agreement with prior ﬁndings that plant-based inhibitors
have mild inhibition on α-amylase and a strong inhibition over α-
glucosidase (Kwon et al., 2010; Ramith et al., 2014).
Presence of excessive free glucose units carries certain amount of
secondary complications and they are also to be addressed while de-
signing an optimum antidiabetic therapy. Incidentally, polyol pathway
which is a component of the intermediarymetabolism is affected during
the presence of excessive glucose levels. Studies suggest that about 3%
of glucose is metabolised through this pathway during normoglycemic
conditions, whereas, during hyperglycaemic state, utilization of glucose
is enhanced to more than 30% (Gonzalez et al., 1984). It is through this
pathway that glucose is converted into sorbitol by the catalysis of aldose
reductase (AR), the rate limiting enzyme of this pathway. Despite the
studies suggesting the role of AR in detoxiﬁcation of aldehydes which
is a by-product of lipid peroxidation, its relevance in carbohydrate
metabolism is unknown. However, inhibition of this enzyme renders a
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(Anthony et al., 1970). This suggests the importance in targeting the in-
hibition of AR during diabetes. In our studies, EF and its constituents
were seen to inhibit aldose reductase activity far better than quercetin,
whichwas used as the positive control in this assay signifying its poten-
tial use in this pathway.
During prolonged hyperglycaemia, the increased blood glucose
levels accelerate the glycation process of various proteins rendering
them inactive, known as Maillard reaction. Though the role of glucose
in the Maillard reaction is well established, more recently, role of fruc-
tose is also identiﬁed to result in protein glycation attributing to its in-
creased intake in the diet. Fructose either can glycate the protein
residues in a non-enzymatic manner or might activate the polyol path-
way which enhances the formation of fructose units from free glucose.
These can in turn participate in protein glycation at a much higher
rate than glucose (Casper et al., 2004). The process of glycation is initi-
ated by the nucleophilic addition reaction between the free amino
group of proteins and the carbonyl group of reducing sugars to yield a
reversible Schiff base formation. This progressively turns into a more ir-
reversible Amadori product like fructosamine, which is characterized as
the early stage of glycation (Ivo, 1994). Reduction of fructosamine is a
potential target for short term control of diabetes and in turn in delay
of vascular complications (Shield et al., 1994). In our study, exposure
of BSA to a high fructose level signiﬁcantly elevated the fructosamine
concentrations in comparison to the non-glycated BSA. Further, treat-
ment with EF and its constituents demonstrated a considerable
decrease in fructosamine. The second stage in glycation involves
the degradation of fructosamines to a range of carbonyl compounds
(namely glyoxal, methylglyoxal and deoxyglucosones) which marks
the intermediate stage of glycation (Singh et al., 2001). Further, these
compounds induce protein oxidation by formation of carbonyl proteins
which leads to a loss of protein thiols which is an efﬁcient indicator of
protein oxidation (Michael, 2001). In the present investigation, the
BSA exposed to a high fructose showed signiﬁcant formation of protein
carbonyl contents and a converse reduction in the protein thiols in
comparison with the non glycated BSA. EF and its components when
treated to such a system signiﬁcantly augmented the formation of pro-
tein carbonyl as well as prevented the loss of protein thiol groups in a
concentration dependent manner. Summing up, these results suggest
the protective ability of the EF and its components in loss of protein
thiol groups and a noteworthy inhibition to the early (formation of
fructosamine) and the intermediary (protein carbonyl formation)
stages of protein glycation process.
The ﬁnal stage is described by the formation of insoluble, ﬂuorescent
advanced glycation end products (AGEs) which coupled with the
glycated proteins play a pivotal role in pathogenesis of vascular compli-
cations of diabetes (Singh et al., 2001). Accumulation of AGE within the
cells leads to impaired protein functions while its presence in the
extracellular matrix results in abnormal cross-linking (Nessar, 2005).
It also generates reactive oxygen species (ROS) by activation of several
signalling cascades by binding to the receptors of AGE on the cell sur-
faces. Association of ROS in oxidative stress and vascular inﬂammation
are among the several complications of postprandial hyperglycaemia
(Samuel and James, 2003). Effect of EF and its constituents on the AGE
formation was studied on the basis of its ﬂuorescent ability which ex-
hibited an antiglycation role throughout the 3 weeks of the experimen-
tal period. These results were superior to the inhibitory and protective
ability exhibited by the synthetic glycation inhibitor aminoguanidine.
The role of widely accepted AGE inhibitor, aminoguanidine is to
reduce the formation of carbonyl intermediates. Some of the other in-
hibitors also play a role acting either as metal chelating agents or as an-
tioxidants. However, the long term implications of these molecules
extend a hepatotoxic effect and thus safer alternatives are in need.
Also, these molecules conﬁscate all the free radicals in vivo which are
not desirable. To prevent these drawbacks, it is advantageous to stimu-
late the antioxidant defences in order to avert protein glycation (Paul,2003; Samuel and James, 2003). In the present study, various in vitro as-
says were performed viz., DPPH, ABTS and superoxide for assessing the
radical scavenging ability. Our results clearly established that EF and its
constituents exhibited a higher free radical scavenging activity in all the
assays used in the study, presenting a protective role against free radical
mediated damage. The studies also revealed a high concentration of
total phenolic content in EF which is well correlated to radical scaveng-
ing activity of the extract. It is recognized that free radicals have a vital
role in autoxidation of unsaturated lipids in food stuffs (Kaur and
Perkins, 1991). A stronger inhibitory potential against lipid oxidation
suggests that EF and its constituents might intercept the free radical
chain of oxidations and contribute hydrogen atom from the phenolic
hydroxyl groups themselves, thereby forming stable free radicals
which do not initiate or propagate further oxidation of lipids.
Although the above assays are based on different principles, it ap-
pears necessary to determine the reducing power of the extract and
its compounds, since it serves as a major indicator of its potential anti-
oxidant activity (Meghashri et al., 2010). The observed dose dependent
increase in the absorbance at 700 nm of the reaction mixture caused by
the reductones (EF and its constituents) was indicative of their in-
creased reducing power. It is self-evident that potent reductones may
also affect ions, particularly Cu2+ and Fe2+. In this regard, iron the
vital mineral for normal physiology, if present in excess, undergoes re-
duction and might form highly reactive hydroxyl radicals contributing
to oxidative stress. An effective way to revert this would be identiﬁca-
tion of a chelating agent which would seize the pro-oxidant potential
from these metal ions (Susanne and Erich, 1999). In food system,
ferrous ions possess maximum pro-oxidant potential and hence in our
study we examined the chelating ability of EF and its constituents
towards the chelation of Fe2+. The results projected a substantial
chelating capacity of the compounds suggesting its interference in the
formation of ferrozine complex from the ferrous ions.
5. Conclusion
In conclusion, EF extends a remarkable antihyperglycaemic effect via
inhibition of carbohydrate hydrolysing enzymes as well as ameliorates
the diabetes induced complications by inhibiting AR and AGE related
pathways. The beneﬁcial effects of EF in are in agreement with the pos-
itive effects of the isolated Umbelliferone and Lupeol, suggesting them
as potential antidiabetic agents. Further, our results are intricately
linked to the antioxidant activities of EF and its constituents which sug-
gest its association with the antidiabetic properties. Also, identiﬁcation
of signiﬁcant amount of Umbelliferone (0.38%) and Lupeol (0.36%) in
EF provided an insight for a strong chemical basis to the alleged beneﬁ-
cial role of EF in antidiabetic properties. However, in vivo studies to
provide a stronger basis for these evidences are essential before it can
be established and incorporated in therapeutic procedures.
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